[8-K] CervoMed Inc. Reports Material Event

Rhea-AI Filing Summary

CervoMed Inc. furnished an update under Regulation FD stating that an investor presentation about its business, clinical studies, development plans and financial position is available on its website under the “Investors – Events and Presentations” section. Company representatives may use this presentation, with possible non‑material changes, in meetings and conferences with investors, analysts and others. The company explains that the presentation is summary information meant to be read together with its SEC filings and other public announcements, and it has no obligation to update it except as required by law. The information is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.

false 0001053691 0001053691 2026-01-07 2026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

January 7, 2026

Date of Report (Date of earliest event reported)

CervoMed Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37942	30-0645032
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
20 Park Plaza, Suite 424 Boston, Massachusetts		02116
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 744-4400

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CRVO		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01         Regulation FD Disclosure

Presentation

Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the “Company,” “we” or “us”) has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.

The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.

--

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01                  Financial Statements and Exhibits

(d)         Exhibits

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2026	CervoMed Inc.
	By:	/s/ William Elder
	Name:	William Elder
	Title:	Chief Financial Officer & General Counsel

FAQ

What did CervoMed Inc. (CRVO) disclose in this 8-K filing?

CervoMed Inc. disclosed that an investor presentation covering its business, clinical studies, development plans, financial position and related matters is available on its website and may be used in meetings with investors, analysts and others.

Where can investors find CervoMed Inc.'s updated investor presentation?

The presentation is available on CervoMed Inc.’s website, www.cervomed.com, under the heading “Investors – Events and Presentations.”

Is the information in CervoMed Inc.'s presentation considered filed with the SEC?

No. The information described in Item 7.01 is being furnished, not filed, so it is not subject to Section 18 of the Exchange Act and is not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

How does CervoMed Inc. describe the investor presentation information?

CervoMed Inc. describes the investor presentation as summary information that should be considered in the context of its SEC filings and other public announcements.

Will CervoMed Inc. update the investor presentation over time?

CervoMed Inc. states it has no duty or obligation to publicly update or revise the information in the presentation except as required by applicable law, although it may choose to do so through future SEC filings or other public disclosures.

Who signed the CervoMed Inc. 8-K related to the investor presentation?

The report was signed on behalf of CervoMed Inc. by William Elder, who is the company’s Chief Financial Officer & General Counsel.